Multiple Sclerosis

Researchers studying patients with relapsing remitting MS in order to determine the relationship between seasonal changes in disease activity in MS and melatonin levels found that determined melatonin was the key factor consistently linked to severity of MS disease activity.

Women with multiple sclerosis who breastfeed their infants exclusively may have a lower risk of disease relapse for up to 6 months postpartum compared to women with MS who do not breastfeed exclusively.

Reduced vitamin D levels may be related to multiple sclerosis (MS) risk, according to findings published in PLOS One.

With each small step made progress towards treatment and prevention of progressive multiple sclerosis creeps closer to becoming a reality, an idea which just a few years ago seemed almost inconceivable.

While there are already several medications and treatments on the market for relapsing multiple sclerosis there continues to be a concerted effort to develop more in an effort to help as many patients as possible.

Recent research suggests that treatment with teriflunomide may slow brain atrophy in patients with relapsing multiple sclerosis.

Patients with multiple sclerosis are no strangers to taking medication for their condition at various times. A new autoinjector recently approved by the FDA hopes to help patients with that process with updated technology and other features to make the process more streamlined and less painful.

The guy microbiome is being studied across the healthcare spectrum as more is learned about this part of a person's anatomy. What it could mean for the treatment of multiple sclerosis has yet to be determined.

There are many factors that can contribute to a person's condition with multiple sclerosis. A recent study looked at what role melatonin can play in the process.

Patients with multiple sclerosis can use mental visual imaging training to improve wellbeing, according to findings published in Restorative Neurology and Neuroscience.

Earlier this year the Consortium of Multiple Sclerosis Centers held its annual conference in Indianapolis with more than 2000 people in attendance. All with the same goal of improving the care they provide their patients with this difficult disease.

There are many factors that patients diagnosed with multiple sclerosis need to consider when managing their condition. While the physical symptoms can be the highest priority, quality of life is an area which is gaining greater recognition in the field.

As the number of treatment options for multiple sclerosis continues to grow patients and their doctors are left to find the right choice for them in order to manage the disease as successfully as possible. This can be a long process that can have a long lasting impact on their overall health.

Even as more medications are developed for relapsing remitting multiple sclerosis patients those with the primary progressive form have been left waiting for news on their condition. According to recent studies the first step in that process may soon be coming to the market.

With doctors having to take on more administrative work in addition to their patient care duties finding systems that can help them accomplish their goals without adding more time consuming tasks can be crucial.

Newer medications for the treatment of multiple sclerosis have been developed in recent years but for some patients interferon remains the starting point for pharmaceutical options.

Just as overactive bladder issues and constipation are an issue for patients with multiple sclerosis, mirabegron is a popular medication in the general population for managing these issues. At the NYU Langone Medical Center Comprehensive Care Center patients receive treatment from a wide variety of healthcare professionals in order to get the best results possible for their condition.

As patients with multiple sclerosis get older memory loss becomes a growing problem. Ways to slow that process including digital technology to help keep a patient's brain sharp.

Optic neuritis is linked to multiple sclerosis and a treatment to help patients with this condition continues to work its way through the research and approval process. Unlike other areas of multiple sclerosis treatment there is no singular way to measure or determine cognitive impairment in patients.

In 1992 the European Committee For Treatment And Research in Multiple Sclerosis met in Barcelona with 200 people in attendance. Twenty three years later the same conference was held in the same city with more than 9000 people in attendance and more than 1000 abstracts submitted.

While many areas of multiple sclerosis treatment have made progress in recent years working to help patients through issues with cognition is still an inexact science though work is being done to correct that.

The ECTRIMS conference may be based in Europe but as the conference has grown so has its global impact on multiple sclerosis treatment. With topics ranging from newly approved therapies to those in the pipeline to those not yet ready for testing there is lots to learn in the yearly event.

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form.

A pair of phase III studies revealed positive efficacy and safety outcomes for ocrelizumab, and this could be a game-changer for patients with multiple sclerosis (MS).

Patients with multiple sclerosis (MS) commonly experience tremoring limbs, head pain, and blurred vision, among other symptoms. Fatigue is another commonly reported and has the power to alter a patient's quality of life (QoL). But by how much?

Results from clinical trials that included patients with relapsing-remitting multiple sclerosis (RRMS) do not appear to be consistent for patients with primary progressive multiple sclerosis (PPMS), according to Markus W. Koch, MD, from the University of Calgary in Alberta, Canada.

It's not uncommon for patients with multiple sclerosis (MS) to experience a reduction in brain volume. However, treatment with alemtuzumab can slow the process, according to a multi-continental team of investigators.

For patients with multiple sclerosis (MS), disturbances in the thermoregulation can result in episodic hypothermia. It's believed that this is caused by hypothalamic lesions from the disease, however, the specifics are not fully understood. M. Toledano and colleagues from the University of Utah set out to uncover more in a poster session that will be presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

Katarina Fink, an associate in the Department of Clinical Neuroscience at the Karolinska Institutet in Sweden, and colleagues analyzed the influence that multiple sclerosis (MS) has on a woman's fertility – an area that has remained unclear. The findings will be described in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.

MR-PET imaging can reveal inflammation and neurodegeneration in the brain, among other things, and a recent study showed that it can also help determine the progression of multiple sclerosis (MS).